{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:36Z","timestamp":1792218636468,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate whether reduced doses (RD) of trastuzumab deruxtecan (T-DXd) or sacituzumab govitecan (SG) provide similar outcomes to the approved standard doses (SD) in metastatic breast cancer (mBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort included mBC patients receiving at least one cycle of SG (April 2021\u2013May 2024) or T-DXd (February 2020\u2013December 2024). Primary outcomes were progression-free survival (PFS) and overall survival (OS). Kaplan\u2013Meier curves and Log-Rank tests estimated and compared PFS and OS from treatment initiation. Subgroup analyses were performed by HER2 and hormone receptor status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>48 patients received SG (24 RD vs. 24 SD) and 66 received T-DXd (29 RD vs. 37 SD). Median PFS for SG was 3\u00a0months in both SD (95% CI, 2\u201310) and RD (95% CI, 2\u20138; p\u2009=\u20090.8). Median OS for SG was 10\u00a0months (95% CI, 7\u201313) for SD and 11\u00a0months (95% CI, 5\u201330; p\u2009=\u20090.4) for RD. For T-DXd, median PFS was 10.4\u00a0months for SD (95% CI, 7.0\u201314.5) and 11.2\u00a0months for RD (95% CI, 5.4\u201331.1; p\u2009=\u20090.8), while median OS was 18.3\u00a0months (95% CI, 13.9\u2013NA) for SD and 28.1\u00a0months (95% CI, 18.2\u2013NA; p\u2009=\u20090.9) for RD. Overall response rates were similar between patients receiving RD and SD SG or T-DXd.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This real-world data suggest RD of SG or T-DXd achieve outcomes comparable to SD, supporting prospective evaluation of lower-dose regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-025-07891-4","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:27:53Z","timestamp":1768901273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort study"],"prefix":"10.1007","volume":"215","author":[{"given":"Nickolas","family":"Stabellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasskiran","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Owusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Moftakhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takae","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia D.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"1","key":"7891_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75(1):10\u201345","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"7891_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41416-020-01161-4","volume":"124","author":"AI Riggio","year":"2021","unstructured":"Riggio AI, Varley KE, Welm AL (2021) The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer 124(1):13\u201326","journal-title":"Br J Cancer"},{"issue":"1","key":"7891_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41523-025-00743-w","volume":"11","author":"AA Davis","year":"2025","unstructured":"Davis AA, Hesse J, Pereira PMR, Ma CX (2025) Novel treatment approaches utilizing antibody-drug conjugates in breast cancer. Npj Breast Cancer 11(1):42","journal-title":"Npj Breast Cancer"},{"issue":"1","key":"7891_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y (2022) Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther 7(1):93","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"7891_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320","journal-title":"N Engl J Med"},{"issue":"16","key":"7891_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384(16):1529\u20131541","journal-title":"N Engl J Med"},{"issue":"13","key":"7891_CR7","doi-asserted-by":"publisher","first-page":"1669592","DOI":"10.3389\/fcell.2025.1669592","volume":"8","author":"D Wu","year":"2025","unstructured":"Wu D, Yang K, He R, Yin R, Shui L (2025) Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs. Front Cell Dev Biol 8(13):1669592","journal-title":"Front Cell Dev Biol"},{"issue":"25","key":"7891_CR8","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382(25):2419\u20132430","journal-title":"N Engl J Med"},{"issue":"1","key":"7891_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A et al (2024) Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 42(1):47\u201358","journal-title":"J Clin Oncol"},{"issue":"31","key":"7891_CR10","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D et al (2023) Trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol 41(31):4852\u20134863","journal-title":"J Clin Oncol"},{"issue":"10","key":"7891_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. JNCI J Natl Cancer Inst 101(10):708\u2013720","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"25","key":"7891_CR12","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/JCO-25-00488","volume":"43","author":"LA Levit","year":"2025","unstructured":"Levit LA, Shah M, Ratain MJ, Garrett-Mayer E, Rahman A, Theoret M, Harvey RD (2025) Totality of the evidence: optimizing dosage selection strategies in oncology. J Clin Oncol 43(25):2827\u20132833","journal-title":"J Clin Oncol"},{"issue":"10","key":"7891_CR13","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1200\/JCO.2007.15.5192","volume":"26","author":"S Sleijfer","year":"2008","unstructured":"Sleijfer S, Wiemer E (2008) Dose selection in phase I studies: why we should always go for the top. J Clin Oncol 26(10):1576\u20131578","journal-title":"J Clin Oncol"},{"issue":"11","key":"7891_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1471-2407-11-131","volume":"12","author":"S Loibl","year":"2011","unstructured":"Loibl S, Skacel T, Nekljudova V, L\u00fcck HJ, Schwenkglenks M, Brodowicz T et al (2011) Evaluating the impact of relative total dose intensity (RTDI) on patients\u2019 short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer 12(11):131","journal-title":"BMC Cancer"},{"issue":"31","key":"7891_CR15","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1200\/JCO.2005.05.0294","volume":"24","author":"V Harvey","year":"2006","unstructured":"Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA et al (2006) Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(31):4963\u20134970","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"7891_CR16","doi-asserted-by":"publisher","first-page":"e2400068","DOI":"10.1200\/OA-24-00068","volume":"2","author":"QJ Khan","year":"2025","unstructured":"Khan QJ, Bohnenkamp C, Monson TE, Phadnis MA, Clark L, Smith HE et al (2025) Randomized trial of fixed-dose capecitabine compared with standard-dose capecitabine in metastatic breast cancer: X-7\/7 trial. JCO Oncol Adv 2(1):e2400068","journal-title":"JCO Oncol Adv"},{"issue":"1","key":"7891_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10549-014-3003-x","volume":"146","author":"T Ambros","year":"2014","unstructured":"Ambros T, Zeichner SB, Zaravinos J, Montero AJ, Ahn E, Aruna M et al (2014) A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat 146(1):7\u201314","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"7891_CR18","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/cpt.2278","volume":"110","author":"MZ Liao","year":"2021","unstructured":"Liao MZ, Lu D, K\u00e5gedal M, Miles D, Samineni D, Liu SN et al (2021) Model-informed therapeutic dose optimization strategies for antibody-drug conjugates in oncology: what can we learn from US food and drug administration-approved antibody-drug conjugates? Clin Pharmacol Ther 110(5):1216\u20131230","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"7891_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP (2023) Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers 15(3):713","journal-title":"Cancers"},{"issue":"1","key":"7891_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M (2018) Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs 36(1):121\u2013135","journal-title":"Invest New Drugs"},{"issue":"5","key":"7891_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.rmr.2025.03.003","volume":"42","author":"L Maurier","year":"2025","unstructured":"Maurier L, Ch\u00e9n\u00e9 AL, Hulo P, Chen J, Sagan C, Pons-Tostivint E (2025) [Diffuse interstitial lung disease induced by antibody-drug conjugates]. Rev Mal Respir 42(5):274\u2013285","journal-title":"Rev Mal Respir"},{"key":"7891_CR22","doi-asserted-by":"crossref","unstructured":"Swain SM, Nishino M, Lancaster LH, Li BT, Nicholson AG, Bartholmai BJ, et al. 2022 Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)\u2013related interstitial lung disease\/pneumonitis\u2014Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev [Internet]. [cited 2025 Aug 25];106. Available from: https:\/\/www.cancertreatmentreviews.com\/article\/S0305-7372%2822%2900042-1\/fulltext","DOI":"10.1016\/j.ctrv.2022.102378"},{"issue":"10","key":"7891_CR23","doi-asserted-by":"publisher","first-page":"9205","DOI":"10.3390\/curroncol30100665","volume":"30","author":"EM Lee","year":"2023","unstructured":"Lee EM, Jim\u00e9nez-Fonseca P, Gal\u00e1n-Moral R, Coca-Membribes S, Fern\u00e1ndez-Montes A, Sorribes E et al (2023) Toxicities and quality of life during cancer treatment in advanced solid tumors. Curr Oncol 30(10):9205\u20139216","journal-title":"Curr Oncol"},{"issue":"1","key":"7891_CR24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1186\/s12885-018-4868-6","volume":"18","author":"J Sibeoni","year":"2018","unstructured":"Sibeoni J, Picard C, Orri M, Labey M, Bousquet G, Verneuil L et al (2018) Patients\u2019 quality of life during active cancer treatment: a qualitative study. BMC Cancer 18(1):951","journal-title":"BMC Cancer"},{"issue":"6","key":"7891_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.clbc.2011.06.005","volume":"11","author":"R Leonard","year":"2011","unstructured":"Leonard R, Hennessy BT, Blum JL, O\u2019Shaughnessy J (2011) Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Clin Breast Cancer 11(6):349\u2013356","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"7891_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10549-016-4075-6","volume":"161","author":"D Yamamoto","year":"2017","unstructured":"Yamamoto D, Sato N, Rai Y, Yamamoto Y, Saito M, Iwata H et al (2017) Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. Breast Cancer Res Treat 161(3):473\u2013482","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"7891_CR27","doi-asserted-by":"publisher","first-page":"e033295","DOI":"10.1161\/JAHA.123.033295","volume":"13","author":"N Stabellini","year":"2024","unstructured":"Stabellini N, Cullen J, Bittencourt MS, Moore JX, Sutton A, Nain P et al (2024) Allostatic Load\/Chronic stress and cardiovascular outcomes in patients diagnosed with breast, lung, or colorectal cancer. J Am Heart Assoc 13(14):e033295","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"7891_CR28","doi-asserted-by":"publisher","first-page":"705","DOI":"10.6004\/jnccn.2023.7023","volume":"21","author":"N Stabellini","year":"2023","unstructured":"Stabellini N, Dmukauskas M, Bittencourt MS, Cullen J, Barda AJ, Moore JX et al (2023) Social determinants of health and racial disparities in cardiac events in breast cancer. J Natl Compr Canc Netw 21(7):705-714.e17","journal-title":"J Natl Compr Canc Netw"},{"key":"7891_CR29","unstructured":"$name [Internet]. [cited 2025 Aug 25]. Available from: https:\/\/www.uhgiving.org\/publications\/annual-report"},{"key":"7891_CR30","unstructured":"R: The R Project for Statistical Computing [Internet]. [cited 2025 Aug 25]. Available from: https:\/\/www.r-project.org\/"},{"key":"7891_CR31","unstructured":"Posit [Internet]. [cited 2025 Aug 25]. Posit. Available from: https:\/\/www.posit.co\/"},{"issue":"9","key":"7891_CR32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821","journal-title":"N Engl J Med"},{"issue":"7","key":"7891_CR33","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/OP.23.00539","volume":"20","author":"A Loeser","year":"2024","unstructured":"Loeser A, Kim JS, Peppercorn J, Burkard ME, Niemierko A, Juric D et al (2024) The right dose: results of a patient advocate-led survey of individuals with metastatic breast cancer regarding treatment-related side effects and views about dosage assessment to optimize quality of life. JCO Oncol Pract 20(7):972\u2013983","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"7891_CR34","doi-asserted-by":"publisher","first-page":"e1807","DOI":"10.1200\/OP.22.00427","volume":"18","author":"RB Jimenez","year":"2022","unstructured":"Jimenez RB, Schenkel C, Levit LA, Hu B, Lei XJ, Harvey RD et al (2022) Oncologists\u2019 perspectives on individualizing dose selection for patients with metastatic cancer. JCO Oncol Pract 18(11):e1807\u2013e1817","journal-title":"JCO Oncol Pract"},{"key":"7891_CR35","unstructured":"Commissioner O of the. Project optimus. FDA [Internet]. 2024 Dec 6 [cited 2025 Sept 25]; Available from: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus"},{"issue":"4","key":"7891_CR36","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","volume":"21","author":"GW Sledge","year":"2003","unstructured":"Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol Off J Am Soc Clin Oncol 21(4):588\u2013592","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"25","key":"7891_CR37","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/JCO-25-00488","volume":"43","author":"LA Levit","year":"2025","unstructured":"Levit LA, Shah M, Ratain MJ, Garrett-Mayer E, Rahman A, Theoret M et al (2025) Totality of the evidence: optimizing dosage selection strategies in oncology. J Clin Oncol 43(25):2827\u20132833","journal-title":"J Clin Oncol"},{"issue":"1","key":"7891_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G et al (2025) Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol OncolJ Hematol Oncol 18(1):51","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"12","key":"7891_CR39","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1016\/j.xphs.2024.10.002","volume":"113","author":"Q Hu","year":"2024","unstructured":"Hu Q, Wang L, Yang Y, Lee JB (2024) Review of dose justifications for antibody-drug conjugate approvals from clinical pharmacology perspective: a focus on exposure-response analyses. J Pharm Sci 113(12):3434\u20133446","journal-title":"J Pharm Sci"},{"key":"7891_CR40","unstructured":"Research C for DE and. Clinical pharmacology considerations for antibody-drug conjugates guidance for industry [Internet]. FDA; 2024 [cited 2025 Aug 26]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-considerations-antibody-drug-conjugates-guidance-industry"},{"issue":"1","key":"7891_CR41","doi-asserted-by":"publisher","first-page":"2230618","DOI":"10.1080\/19420862.2023.2230618","volume":"15","author":"HP Gerber","year":"2023","unstructured":"Gerber HP, Gangwar S, Betts A (2023) Therapeutic index improvement of antibody-drug conjugates. MAbs 15(1):2230618","journal-title":"MAbs"},{"issue":"13","key":"7891_CR42","doi-asserted-by":"publisher","first-page":"1144056","DOI":"10.3389\/fonc.2023.1144056","volume":"3","author":"R Murphy","year":"2023","unstructured":"Murphy R, Halford S, Symeonides SN (2023) Project optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective. Front Oncol 3(13):1144056","journal-title":"Front Oncol"},{"issue":"14","key":"7891_CR43","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.3390\/cancers17142398","volume":"17","author":"LZ R\u00fcsing","year":"2025","unstructured":"R\u00fcsing LZ, Schweighofer J, Aschauer J, Jeryczynski G, Vospernik L, Gisslinger H et al (2025) Optimizing Belantamab Mafodotin in relapsed or refractory multiple myeloma: impact of dose modifications on adverse events and hematologic response in a real-world retrospective study. Cancers 17(14):2398","journal-title":"Cancers"},{"issue":"8","key":"7891_CR44","doi-asserted-by":"publisher","first-page":"458","DOI":"10.47102\/annals-acadmedsg.202576","volume":"54","author":"HY Lee","year":"2025","unstructured":"Lee HY, Shih V, Chan JJ, Liong SZ, Tan RSYC, Ma J et al (2025) Evaluating the impact of relative dose intensity on efficacy of trastuzumab deruxtecan for metastatic breast cancer in the real-world clinical setting. Ann Acad Med Singapore 54(8):458\u2013466","journal-title":"Ann Acad Med Singapore"},{"key":"7891_CR45","doi-asserted-by":"publisher","unstructured":"Chow RD, Sedhom R, Mamtani R. Reduced-dose enfortumab vedotin, treatment continuity, and survival in urothelial cancer. JAMA Oncol [Internet]. 2025 Nov 13 [cited 2025 Dec 20]; Available from: https:\/\/doi.org\/10.1001\/jamaoncol.2025.4566","DOI":"10.1001\/jamaoncol.2025.4566"},{"issue":"2","key":"7891_CR46","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10549-019-05393-8","volume":"178","author":"E Tang","year":"2019","unstructured":"Tang E, Rowland A, McKinnon RA, Sorich MJ, Hopkins AM (2019) Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients. Breast Cancer Res Treat 178(2):473\u2013477","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7891_CR47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA et al (2022) Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. Npj Breast Cancer 8(1):98","journal-title":"Npj Breast Cancer"},{"issue":"16_suppl","key":"7891_CR48","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO.2024.42.16_suppl.1101","volume":"42","author":"JM P\u00e9rez Garc\u00eda","year":"2024","unstructured":"P\u00e9rez Garc\u00eda JM, Gi\u00f3n M, Ruiz-Borrego M, Blancas I, Lopez-Miranda E, Blanch S et al (2024) Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+\/HER2- advanced breast cancer (ABC; PRIMED): a phase 2 trial. J Clin Oncol 42(16_suppl):1101\u20131101","journal-title":"J Clin Oncol"},{"key":"7891_CR49","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Garc\u00eda JM, Gion M, Ruiz-Borrego M, Blancas I, L\u00f3pez-Miranda E, Blanch S, et al. 2025 Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial. eClinicalMedicine [Internet]. [cited 2025 Sept 25];85. Available from: https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(25)00241-X\/fulltext","DOI":"10.1016\/j.eclinm.2025.103309"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07891-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:09:37Z","timestamp":1770034177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07891-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7891"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07891-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"59"}}